S Schreiber

2.4k total citations · 1 hit paper
22 papers, 406 citations indexed

About

S Schreiber is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, S Schreiber has authored 22 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 15 papers in Epidemiology and 7 papers in Surgery. Recurrent topics in S Schreiber's work include Inflammatory Bowel Disease (22 papers), Microscopic Colitis (14 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). S Schreiber is often cited by papers focused on Inflammatory Bowel Disease (22 papers), Microscopic Colitis (14 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). S Schreiber collaborates with scholars based in Germany, United States and Canada. S Schreiber's co-authors include Laurent Peyrin‐Biroulet, Silvio Danese, Walter Reinisch, Camille Boulagnon‐Rombi, Simon Travis, Marie-Danièle Diébold, Virginie Cahn, Guillaume Cadiot, Claire Bastien and Aude Marchal-Bressenot and has published in prestigious journals such as Gut, The American Journal of Gastroenterology and Alimentary Pharmacology & Therapeutics.

In The Last Decade

S Schreiber

20 papers receiving 402 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development and validation of the Nancy histological index for UC

2015 303 citations Aude Marchal-Bressenot, Julia Salleron et al. Gut profile →

Peers

Countries citing papers authored by S Schreiber

Since Specialization

Citations

This map shows the geographic impact of S Schreiber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Schreiber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Schreiber more than expected).

Fields of papers citing papers by S Schreiber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Schreiber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Schreiber. The network helps show where S Schreiber may publish in the future.

Co-authorship network of co-authors of S Schreiber

This figure shows the co-authorship network connecting the top 25 collaborators of S Schreiber. A scholar is included among the top collaborators of S Schreiber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Schreiber. S Schreiber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P1071 Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study 2025 ·Journal of Crohn s and Colitis ·S Schreiber, (unknown), Aoife Keohane, Baojin Zhu, (unknown), Miguel Regueiro, David Hudesman, Yunfei Chen, C. Owen	1
2	Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes 2025 ·RMD Open ·Xavier Mariette, Sven Borchmann, Sandrine Aspeslagh, Zoltán Szekanecz, Christina Charles‐Schoeman, S Schreiber, Ernest Choy, Laurent Peyrin‐Biroulet, Marc Schmalzing, Yoshiya Tanaka, Hugo Ten Cate, René Westhovens, C. Janneke van der Woude, (unknown), (unknown), (unknown), (unknown), Chris Watson, (unknown), Andreas Stallmach	1
3	P0833 Trajectories of response in patients with moderately-to-severely active Crohn’s disease treated with mirikizumab or ustekinumab: Post hoc results from the VIVID-1 study 2025 ·Journal of Crohn s and Colitis ·S Schreiber, (unknown), Gang Yu, Laurie Keefer, A Ananthakrishnan, G. D’Haens, Parakkal Deepak, (unknown), Gil Melmed, Yunfei Chen, (unknown)	2
4	OP39 Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active ulcerative colitis – Results from TUSCANY-2 2025 ·Journal of Crohn s and Colitis ·Vipul Jairath, Jessica R. Allegretti, Andrés Yarur, Silvio Danese, S Schreiber, (unknown), Jarosław Kierkuś, Rupert W. Leong, Michael S. Vincent, Anindita Banerjee, (unknown), (unknown), Srividya Neelakantan, Kenneth E. Hung, Daniela Bojic, Karen Lasch, Courtney Schiffman, (unknown)	1
5	A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis 2025 ·Clinical Gastroenterology and Hepatology ·Bruce E. Sands, S Schreiber, Silvio Danese, Jarosław Kierkuś, Brihad Abhyankar, Michael Y. Choi, (unknown), Yujun Wu, Fangui Sun, Dooyoung Lee, Dan Cui, (unknown), (unknown), (unknown), Bruce N. Rogers, Laurent Peyrin‐Biroulet, Brian G. Feagan	0
6	Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study 2025 ·The Lancet. Gastroenterology & hepatology ·Remo Panaccione, Séverine Vermeire, Silvio Danese, Peter Higgins, Gary R. Lichtenstein, Hiroshi Nakase, Sarah C. Glover, (unknown), Jason Eccleston, (unknown), Valencia P. Remple, Xuan Yao, Ziqian Geng, Hannah Palac, Dolly Sharma, (unknown), S Schreiber	2
7	P0834 Mucosal improvement and histologic healing with amiselimod for active Ulcerative Colitis: a phase 2, randomised, placebo-controlled trial 2025 ·Journal of Crohn s and Colitis ·S Schreiber, (unknown), (unknown), Robert J. Israel, Juhyun Lee, S. Hanauer	2
8	DOP061 RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active ulcerative colitis – Findings from the phase IIb TUSCANY-2 trial 2025 ·Journal of Crohn s and Colitis ·Jessica R. Allegretti, Andrés Yarur, (unknown), Silvio Danese, S Schreiber, (unknown), Christina Ha, Jarosław Kierkuś, Rupert W. Leong, Michael S. Vincent, Anindita Banerjee, (unknown), Elena Peeva, Srividya Neelakantan, Kenneth E. Hung, Daniela Bojic, Karen Lasch, Courtney Schiffman, Vipul Jairath	1
9	OP09 Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella study 2024 ·Journal of Crohn s and Colitis ·Séverine Vermeire, Jessica R. Allegretti, (unknown), Millie D. Long, Jarosław Leszczyszyn, S Schreiber, (unknown), Jarosław Kierkuś, (unknown), Michael S. Vincent, (unknown), (unknown), Anindita Banerjee, Jeremy D. Gale, Kenneth E. Hung	3
10	Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12 2024 ·Inflammatory Bowel Diseases ·Alessandro Armuzzi, David T. Rubin, S Schreiber, Julián Panés, (unknown), (unknown), David Gruben, Martina Goetsch, Abhishek Bhattacharjee, María Chaparro, Marla C. Dubinsky	1
11	DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial 2024 ·Journal of Crohn s and Colitis ·Laurent Peyrin‐Biroulet, Peter Bossuyt, Miguel Regueiro, S Schreiber, K Gecse, Peter M. Irving, Geert D’Haens, Qian Cao, Ezequiel Neimark, (unknown), (unknown), Kristina Kligys, Daniel J. O’Brien, Remo Panaccione	9
12	S1127 A Randomized, Double-Blind, Placebo-Controlled Trial of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease: Design and Rationale for the VICTRIVA Study 2024 ·The American Journal of Gastroenterology ·Silvio Danese, Bruce E. Sands, Brian G. Feagan, Vipul Jairath, (unknown), Laurent Peyrin‐Biroulet, Peter M. Irving, S Schreiber, Iris Dotan, Marc Ferrante, Geert D’Haens, Stephen L. Jones, Marcelo Freire, Dirk Lindner, Shashi Adsul, (unknown), Jean–Frédéric Colombel	0
13	S1474 Efficacy and Safety of Upadacitinib After 3 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Long-Term Data From the Phase 3 Open-Label Extension Study (U-ACTIVATE) 2024 ·The American Journal of Gastroenterology ·Remo Panaccione, Peter Higgins, Hiroshi Nakase, Sarah C. Glover, Silvio Danese, Jean‐Frédéric Colombel, Jason Eccleston, (unknown), Valencia P. Remple, Xuan Yao, (unknown), S Schreiber	1
14	OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies 2023 ·Journal of Crohn s and Colitis ·B G Feagan, (unknown), (unknown), JO Lindsay, (unknown), (unknown), Ana P. Lacerda, (unknown), (unknown), Qian Zhou, (unknown), M Chen, S Schreiber	2
15	P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials 2023 ·Journal of Crohn s and Colitis ·Laurent Peyrin‐Biroulet, Marla C. Dubinsky, B E Sands, Julián Panés, S Schreiber, Walter Reinisch, B G Feagan, Silvio Danese, Andrés Yarur, Geert D’Haens, (unknown), (unknown), Joseph Wu, Irene Modesto, (unknown), (unknown), (unknown), Séverine Vermeire	4
16	P630 Upadacitinib Improves Clinical Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies 2023 ·Journal of Crohn s and Colitis ·S Schreiber, A. J. Lim, Ana P. Lacerda, Jessica R. Allegretti, Kenji Watanabe, Dana J. Lukin, (unknown), (unknown), (unknown), Qian Zhou, (unknown), Édouard Louis	2
17	P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial 2023 ·Journal of Crohn s and Colitis ·S Schreiber, (unknown), C. Janneke van der Woude, Ignacio Marín‐Jiménez, Douglas C. Wolf, Elisabeth Schnoy, Bruce Salzberg, (unknown), (unknown), Wayne Langholff, (unknown), C Gasink, Thomas Baker, (unknown), B G Feagan, (unknown)	8
18	P151 Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations 2023 ·Journal of Crohn s and Colitis ·S Schreiber, Silvio Danese, A Dignass, Eugeni Domènech, Massimo Claudio Fantini, (unknown), Jonas Halfvarson, Adam Hart, Fernando Magro, Charlie W. Lees, (unknown), (unknown), (unknown), (unknown), Laurent Peyrin‐Biroulet	3
19	Development and validation of the Nancy histological index for UC breakdown → 2015 ·Gut ·Aude Marchal-Bressenot, Julia Salleron, Camille Boulagnon‐Rombi, Claire Bastien, Virginie Cahn, Guillaume Cadiot, Marie-Danièle Diébold, Silvio Danese, Walter Reinisch, S Schreiber, Simon Travis, Laurent Peyrin‐Biroulet	303
20	Neue Biologika für die Behandlung chronisch-entzündlicher Darmerkrankungen 2014 ·Der Internist ·S Schreiber, Oliver Bachmann	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact